• Orum Therapeutics dosed the first patient in a Phase 1 trial of ORM-1153 for relapsed or refractory AML.
• No clinical results have been presented; the study is designed to generate initial safety, pharmacology, and early activity readouts.
• Program targets CD123 with a GSPT1 degrader payload, positioning it as a new approach for CD123-expressing blood cancers.
• Trial plans to enroll about 42 patients across multiple U.S. sites, with potential expansion to other regions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610131900PRIMZONEFULLFEED9844809) on October 13, 2026, and is solely responsible for the information contained therein.